Tuesday, July 5, 2022

Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Intel Corp. (INTC) and Qualcomm Inc. (QCOM). These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.

You can see all research reports from today here >>>

Novo Nordisk Shares have outperformed the industry of Zacks Large Cap Pharmaceuticals over the past year (+32.6% vs. +20.1%) thanks to the company’s promising diabetes drug, Ozempic. The Zacks analyst described the launch of Rybelsus as a further strengthening of Novo Nordisk’s best-in-class diabetes portfolio.

Ozempic, Rybelsus, Xultophy and Saxenda helped the company maintain momentum. Expanding the labels of these existing drugs should boost sales.

However, lower realized prices in the United States, loss of product exclusivity and stiff competition are affecting sales totals. PThe impending expiration of some of the products in Novo Nordisk’s portfolio is of concern. Sales continue to be negatively impacted by the Covid pandemic. Wegovy’s supply issues also hurt the stock.

(You can read the full Novo Nordisk research report here >>>)

Intel shares are down -28.3% year-to-date compared to Zacks Semiconductor – General Industry’s -41.6% decline. The Major in Chip Manufacturing reaffirmed its earlier guidance for 2022 despite near-term headwinds as it expects demand to pick up in the second half.

The company is banking on the prospects for the Internet of Things and Mobileye businesses. Mobileye’s growth is expected to be driven by design gains in a recovering automotive sector. The recovery in the enterprise sector of the data center segment is positive. Intel is developing more integrated solutions that are likely to be competitive on a cost-per-watt basis while offering custom solutions for large enterprises.

(You can read the full Intel research report here >>>)

Qualcomm shares are down -10.9% over the past year against the -16.7% decline in wireless equipment industry Zacks. The company faces intense competition from low-cost chipmakers. High research and development costs are expected to squeeze margins, while a global chip shortage due to supply chain disruptions is a headwind. It is susceptible to risks from lower handset shipments, particularly in China.

However, Qualcomm is focused on maintaining its leadership in the 5G and chipset market, delivering resilient, low-power multi-gigabit connectivity with best-in-class security. He sees healthy traction in EDGE networking solutions across various industries.

The acquisition of Arriver will strengthen its ability to provide automakers with fully integrated advanced driver assistance system solutions. The company is well positioned to benefit from strong 5G traction with greater visibility and diversified business to meet its long-term revenue goals.

(You can read the full Qcom research report here >>>)

Other noteworthy reports we feature today include T-Mobile US, Inc. (TMUS), Blackstone Inc. (BX), and Sony Group Corp. (SONY).

Marc Vickery
Senior Writer

Note: Sheraz Mian leads the equity research department at Zacks and is a well-known expert on overall earnings. He is frequently quoted in the written and electronic press and publishes the weekly Earnings trendthe sand Revenue overview reports. If you would like to receive an email notification whenever Sheraz publishes a new article, please click here>>>

Previous

Encryption Software Market 2022-2030: Growing Need for Cloud Multitenancy and Securing Remote Offices

Next

"Lost the Fire, Lost the Spark"

Check Also